Related news from
Thu, 19 Feb 2026 12:56:00 +0000	COR's MWI Animal Health to Merge With Covetrus in $3.5 Billion Deal Cencora is set to merge MWI Animal Health with Covetrus in a $3.5B deal, retaining a 34.3% stake as it unlocks capital and targets animal health growth.
Wed, 18 Feb 2026 16:18:50 +0000	Top Midday Stories: Palo Alto Networks Shares Fall After Weak EPS Guidance; Meta Partners With Nvidia to Build Hyperscale Data Centers All three major US stock indexes were up in late-morning trading Wednesday ahead of the afternoon re
Wed, 18 Feb 2026 12:17:17 +0000	Cencora's animal health unit to merge with Covetrus in $3.5 billion deal Feb 18 (Reuters) - Drug distributor Cencora will merge its MWI Animal Health with privately held Covetrus in a deal valuing the unit at $3.5 billion, the companies said on Wednesday, creating a
Wed, 18 Feb 2026 12:00:00 +0000	Covetrus and MWI Animal Health to Merge CONSHOHOCKEN, Pa. & PORTLAND, Maine, February 18, 2026--Cencora (NYSE: COR) and Covetrus, a global animal health technology and services company, today announced that they have entered into a definitive agreement under which Covetrus and MWI Animal Health (MWI) will merge, creating a combined company offering a comprehensive animal health platform.
Tue, 17 Feb 2026 13:52:00 +0000	Is the Options Market Predicting a Spike in Cencora Stock? Investors need to pay close attention to COR stock based on the movements in the options market lately.
Fri, 13 Feb 2026 21:15:00 +0000	Cencora Closes $3.0 Billion Senior Notes Offering CONSHOHOCKEN, Pa., February 13, 2026--Cencora, Inc. (NYSE: COR) today announced the closing of its public offering of $500 million aggregate principal amount of its 3.950% Senior Notes due February 13, 2029 (the "2029 Notes"), $500 million aggregate principal amount of its 4.250% Senior Notes due November 15, 2030 (the "2030 Notes"), $500 million aggregate principal amount of its 4.600% Senior Notes due February 13, 2033 (the "2033 Notes"), $1.0 billion aggregate principal amount of its 4.900% S
Fri, 13 Feb 2026 20:51:14 +0000	Cencora, Azenta, The Pennant Group, LifeStance Health Group, and Gilead Sciences Shares Are Soaring, What You Need To Know A number of stocks jumped in the afternoon session after a softer-than-expected inflation report fueled hopes for interest rate cuts by the Federal Reserve. The January Consumer Price Index (CPI), a key measure of inflation, rose by 0.2%, which was less than economists had forecast, with the annual rate cooling to 2.4%. This encouraging data increased market expectations for the Fed to begin cutting interest rates as early as June. The news prompted a rally in Treasuries as their yields fell. Wh
Thu, 12 Feb 2026 13:10:43 +0000	Cencora (COR) Valuation Check After Strong Multi‑Year Shareholder Returns Cencora (COR) has moved higher recently. With the shares last closing at $365.70, many investors are revisiting the pharmaceutical distributor’s long term return profile and current valuation signals. See our latest analysis for Cencora. The recent 1 day share price return of 1.58% and 7 day share price return of 10.83% sit against a far stronger long term picture, with 1 year total shareholder return of 51.29% and 5 year total shareholder return of 265.50%, suggesting momentum has been...
Thu, 12 Feb 2026 04:37:34 +0000	1 Momentum Stock with Impressive Fundamentals and 2 We Question The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.
Wed, 11 Feb 2026 05:36:12 +0000	5 Revealing Analyst Questions From Cencora’s Q4 Earnings Call Cencora's fourth quarter was marked by a negative market reaction, as revenue missed Wall Street’s expectations despite year-over-year growth. Management attributed performance to continued growth in its U.S. healthcare solutions, particularly specialty pharmaceuticals and new contributions from recent acquisitions. CEO Robert Mauch emphasized the impact of enhanced operational capabilities and highlighted the integration of Retina Consultants of America (RCA) and the completion of the OneOncolo
Tue, 10 Feb 2026 22:15:00 +0000	Cencora Prices $500 Million 3.950% Senior Notes Due 2029, $500 Million 4.250% Senior Notes Due 2030, $500 Million 4.600% Senior Notes Due 2033, $1.0 Billion 4.900% Senior Notes Due 2036 and $500 Million 5.650% Senior Notes Due 2056 CONSHOHOCKEN, Pa., February 10, 2026--Cencora, Inc. (NYSE: COR) today announced that it priced $500 million aggregate principal amount of its 3.950% Senior Notes due February 13, 2029 (the "2029 Notes"), $500 million aggregate principal amount of its 4.250% Senior Notes due November 15, 2030 (the "2030 Notes"), $500 million aggregate principal amount of its 4.600% Senior Notes due February 13, 2033 (the "2033 Notes"), $1.0 billion aggregate principal amount of its 4.900% Senior Notes due Februar
Tue, 10 Feb 2026 12:31:35 +0000	What Are Wall Street Analysts' Target Price for Cencora Stock? Cencora has consistently outperformed the broader market over the past year, and analysts are maintaining a strongly bullish outlook on the company’s growth and earnings potential.
Mon, 09 Feb 2026 15:30:00 +0000	Chief Executives for Corporate Purpose Announces Covista Chairman and CEO Steve Beard, Cencora Inc. Former Executive Chair Steven H. Collis, and Ann Fairchild, interim President and CEO of Siemens USA Joining Board of Directors NEW YORK CITY, NY / ACCESS Newswire / February 9, 2026 / Chief Executives for Corporate Purpose® (CECP) announced today that three distinguished executives will join the organization's Board of Directors: Steve Beard, Chairman and CEO of Covista, ...
Mon, 09 Feb 2026 13:05:04 +0000	Morgan Stanley Raises Cardinal Health, Inc. (CAH) Price Target After Strong Q2 Cardinal Health, Inc. (NYSE:CAH) is included among 12 Unstoppable Dividend Stocks to Buy According to Analysts. Morgan Stanley boosted its price recommendation on Cardinal Health, Inc. (NYSE:CAH) to $255 from $245 on February 6. The firm kept an Overweight rating on the stock. In a research note, the analyst said the firm updated its view […]
Sun, 08 Feb 2026 07:04:45 +0000	Is It Too Late To Consider Cencora (COR) After A 46% One-Year Rally? If you are wondering whether Cencora's current share price still offers value, you are not alone. The stock has attracted a lot of attention from investors trying to work out what a fair price really looks like. Cencora's shares recently closed at US$359.25, with returns of 0.0% over 7 days, 7.0% over 30 days, 6.0% year to date, 46.0% over 1 year, 131.5% over 3 years and 259.5% over 5 years. This naturally raises questions about how much future upside or risk is now priced in. Recent...
Fri, 06 Feb 2026 14:28:00 +0000	Low Volatility ETFs to Watch Amid Major Tech Sell-Off Over AI Panic USMV and other low-volatility ETFs gain appeal as an AI-driven tech rout wipes $1T, spikes VIX, and fuels rotation into staples and value sectors.
Thu, 05 Feb 2026 20:31:00 +0000	Cencora (COR) Stock Trades Up, Here Is Why Shares of healthcare distributor Cencora (NYSE:COR) jumped 7.1% in the afternoon session after the company reported first-quarter results that beat profit expectations and raised its full-year guidance.
Thu, 05 Feb 2026 17:48:00 +0000	Cardinal Health Stock Jumps After Earnings. Its CEO Explains What Went Right. Less than a month after raising its fiscal-year outlook, Cardinal Health hiked it again. The company, which distributes pharmaceuticals and other medical supplies to customers like CVS Health said Thursday that it now expects adjusted earnings in the range of $10.15 to $10.35 a share for the current fiscal year. The company’s previous forecast, which it provided at the J.P. Morgan Healthcare Conference last month, called for profit of at least $10 a share.
Thu, 05 Feb 2026 06:13:11 +0000	Cencora Q1 Earnings Call Highlights Cencora (NYSE:COR) reported a strong start to fiscal 2026 and raised key elements of its full-year outlook after completing the acquisition of a majority stake in OneOncology. Management highlighted continued momentum in the company’s U.S. Healthcare Solutions segment, benefits from its pharmaceutic
Thu, 05 Feb 2026 05:34:31 +0000	COR Q4 Deep Dive: Specialty Expansion and OneOncology Drive Strategic Shifts Healthcare distributor Cencora (NYSE:COR) fell short of the market’s revenue expectations in Q4 CY2025, but sales rose 5.5% year on year to $85.93 billion. Its non-GAAP profit of $4.08 per share was 1% above analysts’ consensus estimates.

If you are already a Value Forum member but are not logged on, click here to log on. If you are a guest, thank you for visiting ValueForum -- click here for information about guest access or click here to join -- a Trial Pass can be purchased for $6.99 to help you decide if you want to commit to longer term membership. Did you know there are customized portals into VF like REITs.ValueForum.com and also My ValueForum which lets you customize your VF experience to the posters and topics that most interest you!